CER-001

N/A

Report date: 2025/03/26 15:47:45

Base Information

Drug NameCER-001
Drug Alias NameCerenis HDLRecombinant Human Apolipoprotein A-IRecombinant Human Apolipoprotein A-I/Phospholipids complexCER-001
ClassificationBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionApolipoprotein A-I stimulantsHDL-cholesterol stimulants
TargetsApolipoprotein A-IHDL-cholesterol
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaHomozygous familial hypercholesterolemiaHypoalphalipoproteinemias +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumCanadaUnited States +[10] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCerenis Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAcademic Medical CenterCerenis Therapeutics Sa
Active IndicationsN/A
Inactive IndicationsHeterozygous familial hypercholesterolemiaHomozygous familial hypercholesterolemiaHypoalphalipoproteinemias +[5] 

Other Information

ATC CodeN/A
Related LinksN/A